Xeris Pharmaceuticals, Inc. Q1 2026 Earnings Recap

Xeris Biopharma's shares rose modestly by 2.5% following Q1 results that showed solid revenue growth driven by Recorlev's strong performance, while Gvoke’s sales were hampered by Medicare-related headwinds, tempering broader enthusiasm.

Key Takeaways

• Total revenue grew 38% year-over-year to $83.1 million, with net product revenue up 43% to $82.5 million.
• Recorlev revenue nearly doubled (+95%) to approximately $50 million, driven by record referrals and new patient starts, especially post-Q1 payer resets.
• Gvoke revenue remained flat year-over-year at $20.8 million, impacted by Medicare policy and plan changes that increased out-of-pocket costs and reduced prescription fills.
• Keveyis posted a modest 4% revenue increase to around $12 million, marking its second consecutive quarter of year-over-year growth.
• XP-8121 remains on track for Phase III initiation later this year, leveraging existing commercial and technological capabilities.